ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1015

Pro-Inflammatory Cytokines Produced By Different Subsets of Peripheral Blood Mononuclear Cells Are Associated with Ro52/TRIM21 Deficiency in Patients with Inflammatory Myopathies

Ana Barrera-Vargas1, Angeles Shunashy Galindo-Feria2, Diana Gómez-Martín1, Javier Merayo-Chalico1 and Jorge Alcocer-Varela1, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: inflammatory cytokines, inflammatory myositis and interferons

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Muscle Biology, Myositis and Myopathies

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of rare, heterogeneous autoimmune diseases of unknown etiology. Different physiopathogenic mechanisms have been proposed, including the production of autoantibodies and pathogenic cytokines. Ro52/TRIM21 is a ubiquitin ligase, and antibodies against this molecule have been described in different autoimmune diseases, including IIM. The aim of this study was to assess if there is a differential production of cytokines, associated with Ro52/TRIM 21 levels, in patients with recent-onset IIM.

Methods: We included patients within the first month of IIM diagnosis according to Bohan and Peter’s criteria. They all had active disease, had no treatment, and were seen at a tertiary care center between 2013 and 2015. Patients with diagnosis of dermatomyositis (DM), polymyositis and antisynthetase syndrome, as well as age and gender-matched healthy donors were recruited. PBMCs were isolated by Ficoll-Hypaque. CD4+ T cells and monocytes (CD14+) were purified by magnetic selection. Effector T cells were stimulated with PMA plus ionomycin and monocytes with LPS. Supernatants were collected and cytokine levels were measured. Levels of IFN-α were determined by ELISA, and the other cytokines were assessed by cytometric bead array. The expression of TRIM21 in different PBMC subsets was evaluated by Western Blot.

Results: We included 15 patients with IIM and 15 healthy controls. DM was the most prevalent IIM (73.3%). Most patients were female (66%), with a mean age of 43 ± 15 years. After stimulation, T cells from IIM patients had a higher production of IL-17 (80.22 ± 28.57 vs 14.7 ± 5.47, p=0.017) and TNF-α (2325.1 ± 405.14 vs 1055.62 ± 235.21, p=0.005) than healthy controls. After being stimulated with LPS, monocytes from IIM patients produced more IL-6 (8441.2 ± 1801.03 vs 1996.6 ± 650.58, p=0.003) and IFN-α (85.27 ± 13.78 vs 13.3 ± 0.87, p=0.002) than control monocytes. Also, patients with IIM showed a decreased protein expression of TRIM21 in comparison to healthy controls in different PBMC subsets: total PBMC (0.971 ± 0.603 vs 1.849 ± 0.927 p=0.016), CD4+ lymphocytes (0.797 ± 0.54 vs 2.413 ±0.786, p=0.017), and monocytes (0.875 ± 0.358 vs1.89 ±0.209, p<0.001).

Conclusion: Our findings suggest that patients with IIM are characterized by a higher production of proinflammatory cytokines, associated with decreased levels of TRIM21. The deficiency in TRIM21 could potentially lead to decreased IRF ubiquitination and degradation, enhancing type-1 IFN signaling. Along with the higher IFN-α production, this could contribute to the IFN signature found in IIM patients. Also, the specific cytokine profile could represent a potential biomarker for IIM, particularly DM patients.


Disclosure: A. Barrera-Vargas, None; A. S. Galindo-Feria, None; D. Gómez-Martín, None; J. Merayo-Chalico, None; J. Alcocer-Varela, None.

To cite this abstract in AMA style:

Barrera-Vargas A, Galindo-Feria AS, Gómez-Martín D, Merayo-Chalico J, Alcocer-Varela J. Pro-Inflammatory Cytokines Produced By Different Subsets of Peripheral Blood Mononuclear Cells Are Associated with Ro52/TRIM21 Deficiency in Patients with Inflammatory Myopathies [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/pro-inflammatory-cytokines-produced-by-different-subsets-of-peripheral-blood-mononuclear-cells-are-associated-with-ro52trim21-deficiency-in-patients-with-inflammatory-myopathies/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pro-inflammatory-cytokines-produced-by-different-subsets-of-peripheral-blood-mononuclear-cells-are-associated-with-ro52trim21-deficiency-in-patients-with-inflammatory-myopathies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology